​

Ionis Pharmaceuticals (IONS) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Ionis Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$705.14M

Latest Revenue (Q)

$225.25M

Main Segment (Y)

Research and Development Revenue

Ionis Pharmaceuticals Revenue by Period

Ionis Pharmaceuticals Revenue by Year

DateRevenueChange
2024-12-31$705.14M-10.48%
2023-12-31$787.65M34.18%
2022-12-31$587.00M-27.53%
2021-12-31$810.00M11.11%
2020-12-31$729.00M-35.08%
2019-12-31$1.12B87.27%
2018-12-31$599.67M18.12%
2017-12-31$507.67M46.46%
2016-12-31$346.62M22.18%
2015-12-31$283.70M32.47%
2014-12-31$214.16M45.41%
2013-12-31$147.28M44.33%
2012-12-31$102.05M2.99%
2011-12-31$99.09M-8.65%
2010-12-31$108.47M-10.80%
2009-12-31$121.60M13.44%
2008-12-31$107.19M53.96%
2007-12-31$69.62M183.80%
2006-12-31$24.53M-38.87%
2005-12-31$40.13M-5.84%
2004-12-31$42.62M-14.73%
2003-12-31$49.99M-37.65%
2002-12-31$80.18M50.51%
2001-12-31$53.27M43.00%
2000-12-31$37.26M9.90%
1999-12-31$33.90M-13.52%
1998-12-31$39.20M20.62%
1997-12-31$32.50M43.81%
1996-12-31$22.60M73.85%
1995-12-31$13.00M28.71%
1994-12-31$10.10M-16.53%
1993-12-31$12.10M-

Ionis Pharmaceuticals generated $705.14M in revenue during NA 2024, up -10.48% compared to the previous quarter, and up 62.79% compared to the same period a year ago.

Ionis Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-06-30$225.25M88.50%
2024-03-31$119.50M-63.18%
2023-12-31$324.50M125.35%
2023-09-30$144.00M-23.40%
2023-06-30$188.00M43.51%
2023-03-31$131.00M-13.82%
2022-12-31$152.00M-4.86%
2022-09-30$159.77M19.42%
2022-06-30$133.79M-5.73%
2022-03-31$141.92M-67.75%
2021-12-31$440.00M230.60%
2021-09-30$133.09M5.84%
2021-06-30$125.75M12.67%
2021-03-31$111.61M-61.51%
2020-12-31$290.00M81.16%
2020-09-30$160.08M9.99%
2020-06-30$145.54M9.13%
2020-03-31$133.37M-73.00%
2019-12-31$494.00M194.24%
2019-09-30$167.89M2.37%
2019-06-30$164.00M-44.82%
2019-03-31$297.21M54.71%
2018-12-31$192.11M32.13%
2018-09-30$145.40M23.48%
2018-06-30$117.75M-18.47%
2018-03-31$144.42M-16.18%
2017-12-31$172.30M42.50%
2017-09-30$120.91M16.09%
2017-06-30$104.15M-5.58%
2017-03-31$110.30M-31.21%
2016-12-31$160.35M44.55%
2016-09-30$110.93M188.35%
2016-06-30$38.47M4.33%
2016-03-31$36.87M-28.50%
2015-12-31$51.57M4.99%
2015-09-30$49.12M-59.21%
2015-06-30$120.43M92.43%
2015-03-31$62.58M-26.25%
2014-12-31$84.86M92.59%
2014-09-30$44.06M-22.80%
2014-06-30$57.08M102.68%
2014-03-31$28.16M-33.35%
2013-12-31$42.25M79.14%
2013-09-30$23.59M-38.08%
2013-06-30$38.09M-12.15%
2013-03-31$43.36M118.19%
2012-12-31$19.87M71.30%
2012-09-30$11.60M-75.49%
2012-06-30$47.34M103.74%
2012-03-31$23.23M-28.29%
2011-12-31$32.40M56.44%
2011-09-30$20.71M-16.56%
2011-06-30$24.82M17.38%
2011-03-31$21.15M-19.96%
2010-12-31$26.42M-7.70%
2010-09-30$28.62M21.79%
2010-06-30$23.50M-21.46%
2010-03-31$29.93M-7.24%
2009-12-31$32.26M20.51%
2009-09-30$26.77M-13.62%
2009-06-30$30.99M-1.85%
2009-03-31$31.58M52.83%
2008-12-31$20.66M-35.87%
2008-09-30$32.22M-2.26%
2008-06-30$32.96M54.36%
2008-03-31$21.35M-13.64%
2007-12-31$24.73M-

Ionis Pharmaceuticals generated $225.25M in revenue during Q2 2024, up 88.50% compared to the previous quarter, and up 171.95% compared to the same period a year ago.

Ionis Pharmaceuticals Revenue Breakdown

Ionis Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22Dec 21Dec 20
Commercial$293.08M$308.59M$303.36M$342.39M$364.70M
Other$22.59M----
Product$34.19M$34.91M$30.05M$70.00M-
Research and Development Revenue$412.06M$479.06M$284.01M--
SPINRAZA Royalties$216.09M$240.38M---
Collaborative Agreement Revenue$332.65M$352.66M$207.22M--
Other Commercial$56.78M$68.21M---
Licensing and Other Royalties-$33.30M$30.99M$19.12M$8.12M
Spinraza Royalties--$242.31M$267.78M$286.58M
Eplontersen Joint Development Revenue--$76.79M--
TEGSEDI and WAYLIVRA---$55.50M-
Research and Development Revenue Under Collaborative Agreements---$468.06M$364.56M

Ionis Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: Research and Development Revenue (30.13%), Collaborative Agreement Revenue (24.33%), Commercial (21.43%), SPINRAZA Royalties (15.80%), Other Commercial (4.15%), Product (2.50%), and Other (1.65%).

Quarterly Revenue by Product

Product/ServiceDec 24Sep 24Jun 24Dec 23Sep 23Jun 23
Collaborative Agreement Revenue$146.24M$44.88M$141.52M$179.14M$44.17M$91.01M
SPINRAZA Royalties$102.14M$57.21M$56.74M$112.11M$67.25M$61.01M
Commercial$145.31M$75.73M$72.04M$78.84M$84.08M$77.90M
Other Commercial$32.12M$13.15M$11.51M$34.50M$16.83M$16.89M
Product$17.07M$8.92M$8.19M$20.15M$8.29M-
Research and Development Revenue$200.76M$58.08M$153.21M$245.66M$60.13M$110.51M
Licensing and Other Royalties-$4.23M$3.32M$13.71M$8.54M-
Eplontersen Joint Development Revenue----$15.96M$19.50M

Ionis Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Research and Development Revenue (31.19%), Collaborative Agreement Revenue (22.72%), Commercial (22.58%), SPINRAZA Royalties (15.87%), Other Commercial (4.99%), and Product (2.65%).

Ionis Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
INCYIncyte$4.24B$962.99M
BMRNBioMarin Pharmaceutical$2.85B$733.87B
ALNYAlnylam Pharmaceuticals$2.25B$420.15M
EXELExelixis$2.17B$478.06M
SRPTSarepta Therapeutics$1.90B$362.93M
HALOHalozyme Therapeutics$1.02B$290.08M
PTCTPTC Therapeutics$806.78M$135.42M
APLSApellis Pharmaceuticals$709.95M$176.57M
IONSIonis Pharmaceuticals$705.14M$225.25M
KRYSKrystal Biotech$290.51M$83.84M
MDGLMadrigal Pharmaceuticals$180.13M$62.17M
IOVAIovance Biotherapeutics$164.07M$58.55M
ARWRArrowhead Pharmaceuticals$3.55M$2.50M
AKROAkero Therapeutics--
VKTXViking Therapeutics--
TERNTerns Pharmaceuticals--

IONS Revenue FAQ

What is Ionis Pharmaceuticals’s yearly revenue?

Ionis Pharmaceuticals's yearly revenue for 2024 was $705.14M, representing a decrease of -10.48% compared to 2023. The company's yearly revenue for 2023 was $787.65M, representing an increase of 34.18% compared to 2022. IONS's yearly revenue for 2022 was $587M, representing a decrease of -27.53% compared to 2021.

What is Ionis Pharmaceuticals’s quarterly revenue?

Ionis Pharmaceuticals's quarterly revenue for Q2 2024 was $225.25M, a 88.50% increase from the previous quarter (Q1 2024), and a 19.81% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $119.5M, a -63.18% decrease from the previous quarter (Q4 2023), and a -8.78% decrease year-over-year (Q1 2023). IONS's quarterly revenue for Q4 2023 was $324.5M, a 125.35% increase from the previous quarter (Q3 2023), and a 113.49% increase year-over-year (Q4 2022).

What is Ionis Pharmaceuticals’s revenue growth rate?

Ionis Pharmaceuticals's revenue growth rate for the last 3 years (2022-2024) was 20.13%, and for the last 5 years (2020-2024) was -3.27%.

What are Ionis Pharmaceuticals’s revenue streams?

Ionis Pharmaceuticals's revenue streams in c 24 are Commercial, Other, Product, Research and Development Revenue, SPINRAZA Royalties, Collaborative Agreement Revenue, and Other Commercial. Commercial generated $293.08M in revenue, accounting 21.43% of the company's total revenue, down -5.03% year-over-year. Other generated $22.59M in revenue, accounting 1.65% of the company's total revenue Product generated $34.19M in revenue, accounting 2.50% of the company's total revenue, down -2.07% year-over-year. Research and Development Revenue generated $412.06M in revenue, accounting 30.13% of the company's total revenue, down -13.98% year-over-year. SPINRAZA Royalties generated $216.09M in revenue, accounting 15.80% of the company's total revenue, down -10.10% year-over-year. Collaborative Agreement Revenue generated $332.65M in revenue, accounting 24.33% of the company's total revenue, down -5.67% year-over-year. Other Commercial generated $56.78M in revenue, accounting 4.15% of the company's total revenue, down -16.76% year-over-year.

What is Ionis Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Ionis Pharmaceuticals was Research and Development Revenue. This segment made a revenue of $412.06M, representing 30.13% of the company's total revenue.